Therapeutic Potential of Tumour Necrosis Factor-alpha Antagonists in Patients with Chronic Heart Failure

Heart Lung and Circulation

Volumn 22, Issue 5, 2013, Pages 323-327

  Javed, Qamar ^a   Murtaza, Iram ^a  

^a QUAID I AZAM UNIVERSITY   (Pakistan)

Author keywords

Cardiovascular disease; Heart failure; Inflammation; Tumour necrosis factor alpha

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; PLACEBO; THIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL TRIAL (TOPIC); CORONARY ARTERY ANEURYSM; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; HEART FAILURE; HUMAN; INFLAMMATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; ANIMAL; CHRONIC DISEASE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION; HEART FAILURE; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876795148     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2012.12.002     Document Type: Review

References (37)

1. Vendrell J., Fernandez-Real J.M., Gutierrez C., Zamora A., Simon I., Bardaji A., et al. A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis 2003, 167(2):257-264.
2. Dedoussis G.V., Panagiotakos D.B., Vidra N.V., Louizou E., Chrysohoou C., Germanos A., et al. Association between TNF-alpha -308G>A polymorphism and the development of acute coronary syndromes in Greek subjects: the CARDIO2000-GENE Study. Genet Med 2005, 7(6):411-416.
3. Van Hoffen E.D., Van Wichen I., Stuij N., De Jonge C., Klopping J., Lahpor J., et al. In situ expression of cytokines in human heart allografts. Am J Pathol 1996, 149(6):1991-2003.
4. Wan S., DeSmet J.M., Barvais L., Goldstein M., Vincent J.L., LeClerc J.L. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996, 112(3):806-811.
5. Zhao S.P., Xu T.D. Elevated tumor necrosis factor alpha of blood mononuclear cells in patients with congestive heart failure. Int J Cardiol 1999, 71(3):257-261.
6. Bolger A.P., Anker S.D. Tumors necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs 2000, 60(6):1245-1257.
7. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323(4):236-241.
8. Reimold A.M. TNF alpha as therapeutic target: new drugs, more applications. Curr Drug Targets Inflamm Allergy 2002, 1(4):377-392.
9. Deswal A., Bozkurt B., Seta Y., Parilti-Eiswirth S., Hayes F.A., Blosch C., et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999, 99(25):3224-3226.
10. Bozkurt B., Tore-Amione G., Warren M.S., Whitmore J., Soran O.Z., Feldman A.M., et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001, 24(1):27-31.
11. Kapadia S., Lee J., Torre-Amione G., Birdsall H.H. MaT.S., Mann D.L. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995, 96(2):1042-1052.
12. Bozkurt B., Kribbs S.B., Clubb F.J., Michael L.H., Didenko V.V., Hornsby P.J., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97(14):1382-1391.
13. Kubota T., Bounoutas G.S., Miyagishima M., Kadokami T., Sanders V.J., Bruton C., et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 2000, 101(21):2518-2525.
14. Javed Q., Swanson N., Vohra H., Thurston H., Gershlick A. Tumor necrosis factor-alpha eluting stents reduce vascular smooth muscle cell proliferation in saphenous vein organ culture. Exp Mol Pathol 2002, 73(2):104-111.
15. Wolfe F., Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004, 116(5):305-311.
16. Bargangi G., Lari F., Magenta G., Brogna R., Zoli G. Echocardiographic evaluation of anti-tumor necrosis factor-alpha therapy with infliximab in patients without cardiac pathologies. Recenti Prog Med 2010, 101(7-8):289-292.
17. Anker S.D., Coats A.J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002, 86(2-3):123-130.
18. Mann D.L., McMurray J.J., Packer M., Swedberg K., Borer J.S., Colucci W.S. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
19. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003, 107(25):3133-3140.
20. Kwon H.J., Cote T.R., Cuffe M.S., Kramer J.M., Braun M.M. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003, 17(2):233-239.
21. Kadokami T., Frye C., Lemster B., Wagner C.L., Feldman A.M., McTiernan C.F. Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 2001, 104:1094-1097.
22. Listing J., Strangfeld A., Kekow J., Schneider M., Kapelle A., Wassenberg S., et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthritis Rheum 2008, 58(3):667-677.
23. Jacobsson L.T., Turesson C., Gülfe A., Kapetanovic M.C., Petersson I.F., Saxne T., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005, 32(7):1213-1218.
24. Nishida K., Okada Y., Nawata M., Saito K., Tanaka Y. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocrine Journal 2008, 55(1):213-216.
25. Scallon B.J., Moore M.A., Trinh H., Knight D.M., Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7(April (3)):251-259.
26. Wong M., Ziring D., Korin Y., Desai S., Kim S., Gjerston J.B., et al. TNF-α blockade in human diseases: mechanisms and future directions. Clin Immunol 2008, 126(2):121-136.
27. Mugnier B., Balandraud N., Darque A., Roudier C., Roudier J., Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003, 48(7):1849-1852.
28. Hlavaty T., Pierik M., Henckaerts L., Ferrante M., Joossens S., van Schuerbeek N., et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 2005, 22(7):613-626.
29. Oishi T., Fujieda M., Shiraishi T., Ono M., Inoune K., Takahasshi A., et al. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. Circ J 2008, 72:850-852.
30. Quasney M.W., Bronstein D.E., Cantor R.M., Zhang Q., Stroupe C., Shike H., et al. Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with Kawasaki disease. Pediatr Res 2001, 49:686-690.
31. Pierik M., Vermeire S., Steen K., Joossens V., Claessens S., Vlietinck G., et al. Tumors necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004, 20(3):303-310.
32. Han J., Lee J.D., Bibbs L., Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994, 265:808-811.
33. Han J., Richter B., Li Z., Kravchenko V., Ulevitch R.J. Molecular cloning of the p38 MAP kinase. Biochim Biophys Acta 1995, 16:224-227.
34. John C., Lee Jeffrey T., Laydon Peter C., McDonnell Timothy F., Gallagher, Sanjay Kumar, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372(6508):739-746.
35. Lee J.C., Young P.R. Role of CSB/p38/RK stress response kinase in LPS and cytokine signalling mechanisms. J Leukoc Biol 1996, 59:152-157.
36. Fijen J.W., Zijlstra J.G., De Boer P., Spanjersberg R., Cohen Tervaert J.W., Van Der Werf T.S., et al. Supression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol 2001, 124:16-20.
37. Miwatashi S., Arikawa Y., Kotani E., Miyamoto M., Naruo K., Kimura H., et al. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl] benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem 2005, 48(19):5966-5979.